In type 2 diabetes and obesity, GLP-1 agonists are prescribed due to their effect on appetite and homeostatic feeding, and clinical studies report a reduction in fluid intake (34, 35). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.